What is dacomitinib (dacomitinib) and how much does it cost?

Dacomitinib (Dacomitinib) is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by Pfizer of the United States. It not only acts on EGFR (HER1), but also inhibits related proteins such as HER2 and HER4, demonstrating pan-HER inhibitory properties and has a good effect on entering the brain. Compared with first-generation TKIs, dacomitinib can theoretically provide stronger and more durable inhibitory effects by irreversibly binding to EGFR mutant proteins.

Dacomitinib is mainly used to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletions or exon 21 L858R substitution mutations confirmed by genetic testing as a first-line treatment. In clinical trials, dacomitinib showed a significant prolongation of overall survival, up to 34 months, and a good therapeutic effect on NSCLC patients with EGFR gene mutations.

However, the use of dacomitinib may also be associated with some side effects, such as diarrhea, rash, paronychia, stomatitis, loss of appetite, dry skin, weight loss, etc., among which diarrhea and interstitial lung disease are the more serious side effects. Therefore, when using dacomitinib, the patient's response needs to be closely monitored and the dose adjusted based on tolerability.

The original drug dacomitinib has been launched in my country and has been included in the medical insurance reimbursement items. Please consult the local medical insurance reimbursement department for the reimbursement ratio. The original drug, which has a specification of 15 mg and 30 tablets, costs about more than 1,000 yuan after reimbursement by medical insurance, making it convenient for domestic patients to purchase it directly. In addition, there are also generic drugs on the market in Laos, such as 45mg and 30 tablets. The product price of Laos Element Pharmaceuticals is about 1,500 yuan per box, while the price of Lucius Pharmaceuticals is about 1,200 yuan. For questions about the price of dacomitinib, please consult a professional overseas medical consulting company.

In general, dacomitinib, as a highly effectiveEGFR-TKI, provides a new treatment option for EGFR mutation-positive NSCLC patients, and its efficacy and safety have been verified in clinical trials.